Keybanc analyst Sean Eastman downgrades EMCOR Gr (NYSE:EME) from Overweight to Sector Weight.
Merck’s Chronic Cough Treatment Candidate Receives Second Time FDA Rejection
The FDA issued a Complete Response Letter (CRL) regarding Merck & Co Inc's (NYSE: MRK) New Drug Application (NDA) for gefapixant under development for the treatment of refractory chronic cough (RCC) or unexplained chronic